BluGlass Limited Strengthens Photonics Growth with AU$1.4 million Uviquity Phase II Contract
BluGlass Limited (ASX: BLG) has secured a AU$1.4 million Phase II contract from US-based photonics company Uviquity, extending their existing Joint Development Agreement and reinforcing BluGlass’ position in advanced gallium nitride laser technology. The expanded collaboration covers photonic integrated circuit development, wafer and chip processing, advanced packaging, laser integration, and the supply of BluGlass’ visible GaN laser products. Payments will be received in instalments over the next year, beginning in the third quarter of 2026.
The agreement follows the successful completion of Phase I, during which Uviquity achieved the world's first chip-scale 229 nm deep-UV laser, targeting semiconductor, pharmaceutical, environmental, defence, and analytical applications. BluGlass believes the partnership could evolve into a long-term manufacturing supply relationship as Uviquity advances commercialisation of its photonic platform. With its end-to-end laser design, fabrication, and packaging capabilities across Australia and the US, BluGlass continues to strengthen its presence in high-growth industrial, biomedical, scientific, and defence photonics markets while expanding future commercial opportunities.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
BluGlass Limited Strengthens Photonics Growth with AU$1.4 million Uviquity Phase II Contract
BluGlass Limited (ASX: BLG) has secured a AU$1.4 million Phase II contract from US-based photonics company Uviquity, extending their existing Joint Development Agreement and reinforcing BluGlass’ position in advanced gallium nitride laser technology. The expanded collaboration covers photonic integrated circuit development, wafer and chip processing, advanced packaging, laser integration, and the supply of BluGlass’ visible GaN laser products. Payments will be received in instalments over the next year, beginning in the third quarter of 2026.
The agreement follows the successful completion of Phase I, during which Uviquity achieved the world's first chip-scale 229 nm deep-UV laser, targeting semiconductor, pharmaceutical, environmental, defence, and analytical applications. BluGlass believes the partnership could evolve into a long-term manufacturing supply relationship as Uviquity advances commercialisation of its photonic platform. With its end-to-end laser design, fabrication, and packaging capabilities across Australia and the US, BluGlass continues to strengthen its presence in high-growth industrial, biomedical, scientific, and defence photonics markets while expanding future commercial opportunities.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au